Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

被引：48

作者：

Assi, Tarek ^{[1
]}

Kattan, Joseph ^{[1
]}

Rassy, Elie ^{[1
,2
]}

Nassereddine, Hussein ^{[1
]}

Farhat, Fadi ^{[1
]}

Honore, Charles ^{[2
]}

Le Cesne, Axel ^{[2
]}

Adam, Julien ^{[2
]}

Mir, Olivier ^{[2
]}

机构：

[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, Beirut, Lebanon

[2] French Sarcoma Grp, Gustave Roussy Canc Campus, Villejuif, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷

关键词：

Liposarcoma; Soft tissue sarcoma; CDK4; MDM2; Palbociclib; Abemaciclib; Ribociclib; SOFT-TISSUE SARCOMA; PHASE-II; 1ST-LINE TREATMENT; SYNOVIAL SARCOMA; INHIBITOR; CANCER; DOXORUBICIN; ABEMACICLIB; PALBOCICLIB; EFFICACY;

D O I：

10.1016/j.critrevonc.2020.103029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

引用

页数：6

共 50 条

[1] Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
Thill, Marc
Schmidt, Marcus
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[2] Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
Zhou, Yubing
Shen, Jacson K.
Yu, Zujiang
Hornicek, Francis J.
Kan, Quancheng
Duan, Zhenfeng
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (05): : 1573 - 1582
[3] Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Johnston, Stephen
Emde, Anna
Barrios, Carlos
Srock, Stefanie
Neven, Patrick
Martin, Miguel
Cameron, David
Janni, Wolfgang
Gnant, Michael
JNCI CANCER SPECTRUM, 2023, 7 (04)
[4] Targeting CDK4/6 for Anticancer Therapy
Qi, Jiating
Ouyang, Zhuqing
BIOMEDICINES, 2022, 10 (03)
[5] Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors
Chandarlapaty, Sarat
Razavi, Pedram
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1148 - +
[6] Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors
Koehler, Lena
Graf, Franziska
Bergmann, Ralf
Steinbach, Joerg
Pietzsch, Jens
Wuest, Frank
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (02) : 727 - 737
[7] Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells
Jia, Bin
Choy, Edwin
Cote, Gregory
Harmon, David
Ye, Shunan
Kan, Quancheng
Mankin, Henry
Hornicek, Francis
Duan, Zhenfeng
CANCER LETTERS, 2014, 342 (01) : 104 - 112
[8] Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
Foffano, L.
Cucciniello, L.
Nicolo, E.
Migliaccio, I.
Noto, C.
Reduzzi, C.
Malorni, L.
Cristofanilli, M.
Gerratana, L.
Puglisi, F.
Pitigliani, Sandro
BREAST, 2025, 79
[9] Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors
Yoshimoto, Fernanda Hayashida
de Sousa, Cecilia Felix Penido Mendes
Marta, Gustavo Nader
Hanna, Samir Abdallah
CURRENT ONCOLOGY REPORTS, 2023, 25 (10) : 1153 - 1159
[10] Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors
Fernanda Hayashida Yoshimoto
Cecilia Félix Penido Mendes de Sousa
Gustavo Nader Marta
Samir Abdallah Hanna
Current Oncology Reports, 2023, 25 : 1153 - 1159

← 1 2 3 4 5 →